Know Cancer

or
forgot password


N/A
18 Years
N/A
Open (Enrolling)
Both
Melanoma

Thank you

Trial Information

Inclusion Criteria


Inclusion criteria

- Pathologically-proven diagnosis of melanoma.

- Patient must have a test or procedure that has the potential to provide left-over
tissue that can be banked for future research purposes OR the patient has already had
a diagnostic or therapeutic procedure but who has not yet been approached to
participate is also eligible.

Exclusion criteria

- Any patient with significant contraindications to venipuncture (e.g., severe anemia)
will be excluded from blood collection procedures. However, if the patient provides
consent and a paraffin-embedded block or 10-15 unstained slides of their tissue
diagnosis, they will not be excluded from this protocol.

- Any patient unable or unwilling to provide consent.

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

Molecular changes in patients' melanoma tissue

Outcome Description:

Tissue is collected upon consent or upon receipt of parafin block, primary aim will be met when all tissues are collected and analyzed at conclusion of study. Intent is to aid patients and their treating physician when making treatment decisions.

Outcome Time Frame:

at 120 months

Safety Issue:

No

Principal Investigator

Jeffrey Sosman, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Vanderbilt-Ingram Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

VICC MEL 09109

NCT ID:

NCT01205815

Start Date:

June 2010

Completion Date:

January 2020

Related Keywords:

  • Melanoma
  • Melanoma

Name

Location

Vanderbitl-Ingram Cancer CenterNashville, Tennessee